We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+26.23%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$2.44B
AUM Growth
+$792M
Cap. Flow
+$442M
Cap. Flow %
18.15%
Top 10 Hldgs %
14.39%
Holding
5,222
New
2,059
Increased
1,821
Reduced
839
Closed
374

Sector Composition

Rank Sector Weight
1 Technology 12.14%
2 Healthcare 9.57%
3 Financials 8.79%
4 Industrials 7.76%
5 Consumer Discretionary 7.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GOOS
2776
Canada Goose Holdings
GOOS
$850M
$70K ﹤0.01%
3,031
-7,874
-72% -$175K
MGPI icon
2777
MGP Ingredients
MGPI
$389M
$70K ﹤0.01%
+1,905
New +$68.1K
NWPX icon
2778
NWPX Infrastructure Inc
NWPX
$1.11B
$70K ﹤0.01%
+2,791
New +$66.4K
TMDX icon
2779
Transmedics
TMDX
$3.11B
$70K ﹤0.01%
3,896
+514
+15% +$8.04K
WSBF icon
2780
Waterstone Financial
WSBF
$385M
$70K ﹤0.01%
+4,760
New +$67.4K
CATC
2781
DELISTED
CAMBRIDGE BANCORP
CATC
$70K ﹤0.01%
1,174
+1,126
+2,346% +$59.3K
CAJ
2782
DELISTED
Canon, Inc.
CAJ
$70K ﹤0.01%
+3,517
New +$72.8K
ALBO
2783
DELISTED
Albireo Pharma Inc
ALBO
$70K ﹤0.01%
+2,643
New +$62.3K
DS
2784
DELISTED
Drive Shack Inc.
DS
$70K ﹤0.01%
+37,706
New +$61.9K
AERI
2785
DELISTED
Aerie Pharmaceuticals
AERI
$70K ﹤0.01%
+4,742
New +$70.1K
BSTC
2786
DELISTED
BioSpecifics Technologies Corp.
BSTC
$70K ﹤0.01%
+1,148
New +$66.4K
NLSN
2787
DELISTED
Nielsen Holdings plc
NLSN
$70K ﹤0.01%
4,705
-48,040
-91% -$673K
CATO icon
2788
Cato Corp
CATO
$66.7M
$69K ﹤0.01%
+8,391
New +$82.7K
CELH icon
2789
Celsius Holdings
CELH
$7.28B
$69K ﹤0.01%
+17,706
New +$41.7K
EUFN icon
2790
iShares MSCI Europe Financials ETF
EUFN
$4.3B
$69K ﹤0.01%
4,868
-2,117
-30% -$28K
FCBC icon
2791
First Community Bankshares
FCBC
$933M
$69K ﹤0.01%
+3,098
New +$67.1K
LOCO icon
2792
El Pollo Loco
LOCO
$471M
$69K ﹤0.01%
+4,631
New +$59.4K
INVX
2793
Innovex International
INVX
$2.15B
$69K ﹤0.01%
+2,327
New +$71.5K
PFHD
2794
DELISTED
Professional Holding Corp. Class A Common stock
PFHD
$69K ﹤0.01%
+5,019
New +$75.1K
AMAG
2795
DELISTED
AMAG Pharmaceuticals
AMAG
$69K ﹤0.01%
+9,053
New +$69.3K
CNOB icon
2796
Center Bancorp
CNOB
$1.81B
$68K ﹤0.01%
+4,198
New +$59.9K
DTIL icon
2797
Precision BioSciences
DTIL
$201M
$68K ﹤0.01%
272
+237
+677% +$51.9K
KNSA icon
2798
Kiniksa Pharmaceuticals
KNSA
$6.07B
$68K ﹤0.01%
2,688
+1,254
+87% +$26.2K
MANU icon
2799
Manchester United
MANU
$4.02B
$68K ﹤0.01%
4,272
+3,037
+246% +$48.6K
OFLX icon
2800
Omega Flex
OFLX
$291M
$68K ﹤0.01%
+642
New +$61.1K

Similar funds

Tower Research Capital (TRC)'s Q2 2020 Portfolio in Review

As of Q2 2020, Tower Research Capital (TRC) held 5,222 positions worth $2.44B, up 48% from $1.64B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Tower Research Capital (TRC) deployed $442M of net new capital in Q2 2020, opening 2,059 new positions and adding to 1,821 existing holdings. Its largest new stake was Apple: 428,252 shares worth $39.1M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 3.1% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $342M trimmed.

  • Tower Research Capital (TRC)'s largest Q2 2020 buy was Apple: 428,252 shares worth $39.1M.
  • Tower Research Capital (TRC) added most to iPath Series B S&P 500 VIX Short-Term Futures ETN in Q2 2020, an estimated $55.3M increase.
  • Tower Research Capital (TRC)'s biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $342M.
  • Tower Research Capital (TRC) fully exited First Trust Technology AlphaDEX Fund in Q2 2020, selling an estimated $2.52M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 14% of its $2.44B portfolio in Q2 2020.
  • Tower Research Capital (TRC) opened 2,059 new positions and closed 374 in Q2 2020.
  • Tower Research Capital (TRC)'s portfolio value rose 48% quarter-over-quarter to $2.44B.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2020, filed 13 Aug 2020.